Literature DB >> 8049503

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

Y Shimada1, M Rothenberg, S G Hilsenbeck, H A Burris, D Degen, D D Von Hoff.   

Abstract

CPT-11 (irinotecan hydrochloride, 7-ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxy-camptothecin) is a semisynthetic camptothecin derivative developed in Japan. The inhibitory activity of CPT-11 against human tumor colony-forming units from freshly explanted human tumors was explored using a soft agar cloning system. Final CPT-11 concentrations of 0.3-3.0 micrograms/ml were used for a 1 h exposure. At a concentration of 3.0 micrograms/ml antitumor activity was seen against colorectal, ovarian, nonsmall-cell lung, breast cancer and mesothelioma colony-forming units. CPT-11 should have activity against a broad spectrum of tumors in patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049503     DOI: 10.1097/00001813-199404000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  9 in total

1.  Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.

Authors:  Rohit B Kolhatkar; Peter Swaan; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2008-04-26       Impact factor: 4.200

Review 2.  Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  L R Wiseman; A Markham
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

3.  Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.

Authors:  Nirmalkumar Vijayalakshmi; Abhijit Ray; Alexander Malugin; Hamidreza Ghandehari
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

4.  Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.

Authors:  Yasuhide Yamada; Tatsuro Yamaguchi; Hiroshi Matsumoto; Yasushi Ichikawa; Ayumu Goto; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  Invest New Drugs       Date:  2011-09-06       Impact factor: 3.850

5.  Preclinical and phase I trials of topoisomerase I inhibitors.

Authors:  D D Von Hoff; H A Burris; J Eckardt; M Rothenberg; S M Fields; S F Chen; J G Kuhn
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  A risk-benefit assessment of irinotecan in solid tumours.

Authors:  L L Siu; E K Rowinsky
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

7.  Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.

Authors:  H E Ford; D Cunningham; P J Ross; S Rao; G W Aherne; T S Benepal; T Price; A Massey; L Vernillet; G Gruia
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

8.  Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.

Authors:  D Cunningham; S Falk; D Jackson
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

9.  Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.

Authors:  Jing Xie; Xiaomin Zhang; Meiyu Teng; Bo Yu; Shuang Yang; Robert J Lee; Lesheng Teng
Journal:  Int J Nanomedicine       Date:  2016-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.